Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | AGTR1 | P30556 | 4/20 | 0.37 |
| ▸ | DAGLB | Q8NCG7 | 1/20 | 0.36 |
| ▸ | LTB4R2 | Q9NPC1 | 3/20 | 0.35 |
| ▸ | CTSA | P10619 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.34 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.34 |
| ▸ | ITGAL | P20701 | 1/20 | 0.34 |
| ▸ | USP19 | O94966 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4848531 | 0.90 | AGTR1 (0.44) | AGTR1LTB4R2 | |
| SCHEMBL4847245 | 0.88 | ACHE (0.46) | AGTR1LTB4R2 | |
| SCHEMBL4848701 | 0.85 | REN (0.34) | AGTR1LTB4R2ALDH1A1ITGB2ICAM1 | |
| SCHEMBL4845206 | 0.84 | GRM2 (0.40) | ITGB2ICAM1ITGAL | |
| SCHEMBL4843286 | 0.84 | FPR1 (0.35) | AGTR1LTB4R2ITGB2ICAM1ITGAL | |
| SCHEMBL4847479 | 0.83 | ITGAL (0.39) | ITGB2ICAM1ITGAL | |
| Dimethylamine SCHEMBL4845222 | 0.82 | ITGAL (0.36) | AGTR1ITGB2ICAM1ITGAL | |
| SCHEMBL4841624 | 0.82 | ITGAL (0.35) | AGTR1ITGB2ICAM1ITGAL | |
| SCHEMBL4841738 | 0.82 | ITGAL (0.35) | AGTR1LTB4R2ITGB2ICAM1ITGAL | |
| SCHEMBL4844697 | 0.81 | PTGER4 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7342012-B2 | Inhibitors of αLβ2 mediated cell adhesion | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-03-11 | — | — | US | disclosed |
| US-20050148602-A1 | Inhibitors of alphaLbeta2 mediated cell adhesion | TANABE SEIYAKU CO., LTD. | 2005-07-07 | — | — | US | disclosed |
| US-6897225-B1 | Inhibitors of αLβ2 mediated cell adhesion | TANABE SEIYAKU CO., LTD. (JP) | 2005-05-24 | — | — | US | disclosed |
| EP-1307455-B1 | INHIBITORS OF ALPHA-L BETA-2 MEDIATED CELL ADHESION | TANABE SEIYAKU CO (JP) | 2005-04-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148602-A1 | Inhibitors of alphaLbeta2 mediated cell adhesion | ITGB2, ITGA2B, ITGB1 | MEN1 2408/4885KMT2A 1471/4885SMN1; SMN2 1791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.